ArticleFrontiers in genetics2024
BIMSSA: enhancing cancer prediction with salp swarm optimization and ensemble machine learning approaches.
Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Comprehensive Review of Artificial Intelligence for Brain Tumor Analysis: Taxonomy, Robustness, and Open Challenges in Neuro-Oncology.Journal of imaging · 2026Review
- Robust feature selection for cancer microarray data using a hybrid mRMR and Binary Lion Optimization Algorithm.Scientific reports · 2026Article
- Observational
- Development of the Neutrophil-to-Platelet Ratio (NPR) Integrated with Machine Learning for Predicting Early Mortality After Mechanical Thrombectomy in Acute Ischemic Stroke.Journal of inflammation research · 2026Article
- Prediction ofFrontiers in medicine · 2026Article
- Development and validation of a postpartum hemorrhage risk prediction model for advanced maternal age women undergoing vaginal delivery: a comparison of multiple machine learning algorithms.Frontiers in medicine · 2026Article
- A Machine Learning Approach to Differentiate Cold and Hot Syndrome in Viral Pneumonia Integrating Traditional Chinese Medicine and Modern Medicine: Machine Learning Model Development and Validation.JMIR medical informatics · 2025Article
- Evaluating the Nuclear Reaction Optimization (NRO) Algorithm for Gene Selection in Cancer Classification.Diagnostics (Basel, Switzerland) · 2025Article
- Hybrid machine learning models for enhanced arrhythmia detection from ECG signals using autoencoder and convolution features.PloS one · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer rates are rising rapidly, causing global mortality. According to the World Health Organization (WHO), 9.9 million people died from cancer in 2020. Machine learning (ML) helps identify cancer early, reducing deaths. An ML-based cancer diagnostic model can use the patient's genetic information, such as microarray data. Microarray data are high dimensional, which can degrade the performance of the ML-based models. For this, feature selection becomes essential. Methods: Swarm Optimization Algorithm (SSA), Improved Maximum Relevance and Minimum Redundancy (IMRMR), and Boruta form the basis of this work's ML-based model BIMSSA. The BIMSSA model implements a pipelined feature selection method to effectively handle high-dimensional microarray data. Initially, Boruta and IMRMR were applied to extract relevant gene expression aspects. Then, SSA was implemented to optimize feature size. To optimize feature space, five separate machine learning classifiers, Support Vector Machine (SVM), Random Forest (RF), Extreme Learning Machine (ELM), AdaBoost, and XGBoost, were applied as the base learners. Then, majority voting was used to build an ensemble of the top three algorithms. The ensemble ML-based model BIMSSA was evaluated using microarray data from four different cancer types: Adult acute lymphoblastic leukemia and Acute myelogenous leukemia (ALL-AML), Lymphoma, Mixed-lineage leukemia (MLL), and Small round blue cell tumors (SRBCT). Results: In terms of accuracy, the proposed BIMSSA (Boruta + IMRMR + SSA) achieved 96.7% for ALL-AML, 96.2% for Lymphoma, 95.1% for MLL, and 97.1% for the SRBCT cancer datasets, according to the empirical evaluations. Conclusion: The results show that the proposed approach can accurately predict different forms of cancer, which is useful for both physicians and researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.